Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is a prospective, real-world study intended to evaluate the efficacy and safety of pegylated interferon alpha-2b (PegIntron®) combined with targeted immunotherapy in patients with unresectable intermediate and advanced chronic hepatitis B-related hepatocellular carcinoma. This study intends to enroll 20 patients with unresectable intermediate and advanced chronic hepatitis B-related hepatocellular carcinoma who have previously undergone and are currently receiving nucleoside (nucleotide) analog therapy. Subjects who meet the inclusion and exclusion criteria after evaluation will receive Pegasys® combined with targeted immunotherapy. Both targeted therapy and PD-1 inhibitors will be selected based on actual clinical decision-making, using standard therapeutic drugs recommended by the CSCO guidelines. During the study, each 6 weeks will be defined as a treatment cycle, and treatment will continue until disease progression or unacceptable toxicity occurs. Follow-up will be completed according to the protocol until the end of the study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej, bez ograniczeń co do płci
- •Rozpoznany rak wątroby (HBV-HCC), średniozaawansowany lub zaawansowany, który nie da się operować
- •Funkcja wątroby oceniana jako Child-Pugh A lub B (wynik ≤7)
- •Pozytywny wynik na przeciwciała powierzchniowe wirusa B (HBsAg)
- •Co najmniej jeden widoczny guz na badaniach (według kryteriów RECIST 1.1)
- •Ogólny stan zdrowia powalający na leczenie (ECOG 0-2)
- •Spodziewana długość życia minimum 3 miesiące
- •Dobre funkcjonowanie organów wewnętrznych w ostatnim tygodniu przed leczeniem
✗ Disqualifies
- •Inne nowotwory w ciągu ostatnich 5 lat
- •Krwawienia z żołądka lub jelit w ciągu ostatnich 6 miesięcy
- •Przetoki żołądkowo-jelitowe, perforacja jelit lub zapalenie otrzewnej w ciągu ostatnich 6 miesięcy
- •Skrzepy krwi lub zatorowość w ciągu ostatnich 6 miesięcy przed rozpoczęciem badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Jinling Hospital, Nanjing University Medical School
Nanjing, China
Trial contact
Chen chao, Associate Chief Physician
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.